Loading clinical trials...
Loading clinical trials...
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate (FF/VI) Inhalation Powder Delivered Once Daily for 12 Weeks in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry Currently Treated With Low to Mid-strength Inhaled Corticosteroid or Low-strength Combination Therapy.
Conditions
Interventions
GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)
Placebo
Locations
28
China
GSK Investigational Site
Shenzhen, Guangdong, China
GSK Investigational Site
Zhanjiang, Guangdong, China
GSK Investigational Site
Nanning, Guangxi, China
GSK Investigational Site
Haikou, Hainan, China
GSK Investigational Site
Shenyang, Liaoning, China
GSK Investigational Site
Yinchuan, Ningxia, China
Start Date
January 1, 2012
Primary Completion Date
July 1, 2013
Completion Date
July 1, 2013
Last Updated
March 8, 2017
NCT07486401
NCT07219173
NCT02327897
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions